OrbiMed’s GenMark Diagnostics, Inc GNMK Stock Holding History

OrbiMed’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-732,000	Closed	-$10.8M	–	161
2020 Q2	$10.8M	Buy	+732,000	New	+$7.44M	0.15%	97

Other funds holding GNMK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

OrbiMed's GNMK Position: Q3 2020 in Review

OrbiMed sold out of GenMark Diagnostics, Inc (GNMK) in Q3 2020, closing a stake of 732,000 shares — an estimated $10.8M sold.

OrbiMed first reported a position in GNMK in Q2 2020 and held it in 1 quarter. The position peaked at $10.8M in Q2 2020. 163 funds tracked by Wall St. Rank hold GNMK as of Q3 2020.

OrbiMed reported no remaining GenMark Diagnostics, Inc position as of Q3 2020 after selling out during the quarter.
OrbiMed sold 732,000 GenMark Diagnostics, Inc shares in Q3 2020, an estimated $10.8M.
OrbiMed first reported a position in GenMark Diagnostics, Inc in Q2 2020 and held it in 1 quarter.
OrbiMed's GenMark Diagnostics, Inc position peaked at $10.8M in Q2 2020.
163 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q3 2020.

Based on OrbiMed's 13F filing for Q3 2020, filed 16 Nov 2020.